ClinicalTrials.gg
Status unknownNCT04034277Updated Jul 26, 2019

Lee Silverman Voice Treatment Versus Standard Speech Therapy Versus Control in Hypophonia Rehabilitation in MS

An interventional study of Lee Silverman Voice Therapy and Conventional Treatment in Multiple Sclerosis, sponsored by Fondazione Don Carlo Gnocchi ETS. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-07-26.

Sponsored by Fondazione Don Carlo Gnocchi ETS · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2018, registered Jul 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The aim of the study is to identify the most effective method of intervention to reduce hypophonia in PwMS (Patient With Multiple Sclerosis), as a way to optimize the speech-therapy treatment based on scientific evidence. In the previous AB study, we aimed to verify the efficacy of LSVT LOUD® in PwSM: in the present study we will compare different treatment in a larger sample.

Half of the participants will follow the LSVT Loud program, the other half will follow usual care rehabilitation programs.

The results of these groups will be compared with an historical cohort of no treatment patients.

Read the detailed description

The descriptive studies showed that voice problems, in particular hypophonia, are present in 45% to 91% of patients with multiple sclerosis and may constitute a limitation in social life participation. Although voice, speech and communication are significant aspects for the biopsychosocialwell-being and life quality, only 2% of the PwMS had received any speech therapy and, at the same time, few studies assessed the effects of speech treatment for PwMS.

In according to the taxonomy of voice therapy, the conventional treatment may include direct interventions such as vocal function and modification of respiratory function.

The LSVT LOUD® treatment is a standardized, research-based speech treatment protocol with established efficacy for Idiopathic Parkinson Disease (IPD) and is well described in a large number of studies. Subsequently, further studies supported the efficacy of LSVT LOUD® in voice rehabilitation in various neurological diseases, including Multiple Sclerosis. In the study of Sapir et al., only two women were treated with LSVT LOUD® and the authors concluded that intensive phonatory-respiratory treatment can produce clinically significant and long-term improvement in vocal function in PwMS. These findings are consistent with suggestion that intensive training can improve function in those parts of the body that are prone to fatigue and that vocal training probably minimizes disuse atrophy and increases muscle strength and coordination.

The content and dose of the SLT (Speech Language Therapy) of dysphonia in MS is poorly defined within the published literature and we did not find any meta-analyzes or guidelines that suggest instructions for therapists.

The purpose of this project is to identify the most effective method of intervention to reduce hypophonia in PwMS, as a way to optimize the speech-therapy treatment based on scientific evidence. The data in literature suggest that LSVT LOUD® may be functional for these aims, although there isn't broad-based study with PwSM.

Fourty Persons with Multiple Sclerosis will be randomly allocated to an experimental group (Lee Silverman Voice Treatment - LSVT LOUD® method) or to a control group following usual care rehabilitation programs.

Also an historical cohort of untreated patients was considered (voice assessment: baseline, after 4 weeks, FU-Follow Up at 6/12 months).

Data collection in both groups will be performed at baseline, after 4 weeks of treatment and after 6-12 months up to the end of the rehabilitation program (FU). In order to evaluate the perceptual impact of the treatment, GIRBAS and VHI will be proposed.

The acoustic variables will be recorded with the software PRAAT: SPL (Sound Pressure Level) of a sustained /ah/, SPL of functional sentences, maximum phonation time, SPL of 1 minute monologue. In addition, the following values were taken in the minute of spontaneous speech: Jitter, shimmer, fundamental frequency, maximum frequency and minimum frequency. The type of MS, Expanded Disability Status Scale (EDSS) , demographic data, disease duration, presence of postural and respiratory problems, presence of depression (Beck Depression Inventory-II - BDI II) , pharmacological treatment and cognitive status (Brief Repeatable Battery of Neuropsychological Tests) will be considered.

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • Voice Disorders
  • Speech and language therapy
  • Lee Silverman voice treatment
03

In context

Multiple Sclerosis

3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 2,386 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Fondazione Don Carlo Gnocchi ETS is the lead sponsor of 41 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Multiple Sclerosis according with McDonald's criteria;
  • absence of relaps in the last month;
  • Mini Mental State Examination (MMSE) > 21 score for a better understanding and adherence to the execution of the proposed exercises;
  • hypophonia (conversation \< 60 dB SPL- distance was kept equal at about 15 cm);
  • ability to understand the aims of the study and acceptance to sign an informed consent;
  • acceptance of the intensity of the treatment;
  • ability to understand the Italian language.

Exclusion criteria

Exclusion Criteria:

  • Presence of other neurological disorders;
  • visual/hearing impairments hindering the rehabilitation program;
  • clinical history of laryngeal cancer, chemotherapy, radiotherapy, head and neck trauma or endotracheal intubation;
  • relapse or sudden changes in their MS symptoms within the previous 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Lee Silverman Voice Therapy

    LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.

    Other: Lee Silverman Voice Therapy

  • Active comparator
    Conventional Treatment

    The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality

    Other: Conventional Treatment

Interventions

  • OtherLee Silverman Voice Therapy

    LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize

  • OtherConventional Treatment

    speech rehabilitation protocol comprehend: * Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness. * Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation.

06

What researchers measure

Primary outcomes

  1. Change in intensity (dB) of 3 sustained /ah/

    All subjects were requested to sustain the vowel /ah/ as long as possible at a comfortable frequency and maximum intensity level. Specific task was given: "Please and say /ah/. Make it strong and steady, and sustain it for as long as you can".

    Time frame: at baseline, at 4 weeks (after the completion of 16 training sessions) and after 6-12 months up to the end of the rehabilitation program (FU)

  2. Change in intensity measured in decibel (dB) of three functional sentences

    all speakers were requested to produce three functional sentences at a comfortable frequency and maximum intensity level. The sentences were the same for all subjects. Specific tasks, identical for each individual, was given: "Please take a deep breath and repeat each sentences with effort voice".

    Time frame: at baseline, at 4 weeks (after the completion of 16 training sessions) and after 6-12 months up to the end of the rehabilitation program (FU)

  3. Change in intensity in conversation measured in decibel (dB)

    A speech sample of approximately one minute of spontaneous conversation was recorded and measured in dB in order to analyze speech intensity. Specific tasks, identical for each individual, was given: "Please speak for at least a minute".

    Time frame: at baseline, at 4 weeks (after the completion of 16 training sessions) and after 6-12 months up to the end of the rehabilitation program (FU)

Secondary outcomes

  1. Change in Maximum Phonation Time (MPT) of three sustained /ah/ (sec.)

    All subjects were requested to sustain the vowel /ah/ as long as possible at a comfortable frequency and maximum intensity level. Specific tasks, identical for each individual, was given: "Please and say /ah/. Make it strong and steady, and sustain it for as long as you can".

    Time frame: at baseline, at 4 weeks (after the completion of 16 training sessions) and after 6-12 months up to the end of the rehabilitation program (FU)

  2. Change in Vocal Handicap Index

    Voice Handicap Index (VHI) is a self-assessed standardized 30-point questionnaire, which includes items on the impact of the voice disorder on daily life. The questionnaire is divided into three subscales covering functional, emotional and physical aspect of voice disorders. Each answer is graded 0 to 4 depending on the frequency of the difficulty: 0 no difficulties, 1 almost never, 2 sometimes, 3 almost always, 4 always.

    Time frame: at baseline, at 4 weeks (after the completion of 16 training sessions) and after 6-12 months up to the end of the rehabilitation program (FU)

  3. Change in GIRBAS

    Tool used to quantify perceptual evaluation of the voice quality. The scale evaluates in particular 5 aspects of voice: Grade, Instability, Roughness, Breathiness, Asthenia, and Strain. Voice quality was assessed by a trained speech therapist, using a scale from 0 to 3 where 0 regular, 1 mildly pronounced, 2 moderate, 3 very pronounced.

    Time frame: at baseline, at 4 weeks (after the completion of 16 training sessions) and after 6-12 months up to the end of the rehabilitation program (FU)

07

Study locations

1 of 1 sites recruiting
  • Fondazione Don Gnocchi Irccs
    Milan, Italy
    • DAVIDE CATTANEO, PhD · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04034277
Lead sponsor
Fondazione Don Carlo Gnocchi ETS
Responsible party
Davide Cattaneo (Research Coordinator Larice Lab., Fondazione Don Carlo Gnocchi ETS) — Principal investigator
First posted
Jul 26, 2019
Start date
Jan 15, 2018
Primary completion
Sep 30, 2019 (estimated)
Completion
Mar 30, 2020 (estimated)
Last update
Jul 26, 2019

Study contacts

Davide Cattaneo, PhD
Contact
dcattaneo@dongnocchi.it
+390240308 ext. 814
Maria Carrozza, PhD
study director · Fondazione Don C. Gnocchi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion